Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis

doi:10.1016/S1076-6332(98)80191-8

Academic Radiology

Volume 5, Issue 7, July 1998, Pages 491-502

https://doi.org/10.1016/S1076-6332(98)80191-8 Get rights and content

Rationale and Objectives.

The authors performed this study to evaluate the pharmacokinetics, dialysability, and safety of gadodiamide injection in patients with severely reduced renal function not treated with renal replacement therapy and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis.

Materials and Methods.

Twenty-seven patients—nine with severely reduced renal function (glomerular filtration rate, 2–10 mL/min), nine undergoing hemodialysis, and nine undergoing continuous ambulatory peritoneal dialysis—were followed up for 5, 8, and 22 days, respectively, after receiving gadodiamide injection (0.1 minol per kilogram body weight).

Results.

Gadodiamide injection caused no changes in renal function. In patients with severely reduced renal function, the elimination half-life of gadodiamide injection was prolonged (34.3 hours ± 22.9) compared with data in healthy volunteers (1.3 hours ± 0.25). An average of 65% of the gadodiamide injected was eliminated during a hemodialysis session. After 22 days of continuous ambulatory peritoneal dialysis, 69% of the total amount of gadodiamide was excreted; this reflects the low peritoneal clearance. In all patients, no metabolism or transmetallation of gadodiamide was found. There were no contrast material-related adverse events.

Conclusion.

Gadodiamide is dialysable and can safely be used in patients with severely impaired renal function or those undergoing hemodialysis or continuous ambulatory peritoneal dialysis. No precautions to increase the elimination are necessary.

References (24)

HvattumE et al.
Detection and quantitation of gadolinium chelates in human serum and urine by high-performance liquid chromatography and post-column derivatization of gadolinium with Arsenazo III
J Pharmaceut Biomed Analg
(1995)
BellinMF et al.
Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure
Magn Reson Imaging
(1992)
HausteinJ et al.
Elimination of Gd-DTPA by means of hemodialysis
Eur J Radiol
(1990)
Van WagonerM et al.
A phase I clinical trial with gadodiamide, a nonionic magnetic resonance imaging enhancement agent
Invest Radiol
(1991)
ReintonV et al.
Pharmacokinetics of gadodiamide in patients with moderately impaired renal function
Acad Radiol
(1994)
Schumann-GiampieriG et al.
Pharmacokinetics of Gd-DTPA in patients with chronicrenal failure
Invest Radiol
(1991)
ChachuatA et al.
Pharmacokinetics and tolerance of Gd-DOTA (DOTAREM) in healthy volunteers and in patients with chronic renal failure
Eur Radiol
(1992)
MoonSS et al.
Hemodialysis for elimination of nonionic contrast medium iohexol after angiography in patients with impaired renal function
Nephron
(1995)
Van KraheT et al.
Pharmakokinetik von gadolinium-DTPA bei dialysepflichtiger chronischer niereninsuffizienz
Roe Foe
(1992)
LacknerK et al.
The dialysability of Gd-DTPA

Bröchner-MortensenJ

A simple method for the determination of glomerular filtration rate

Scand J Clin Lab Invest

(1972)

Normann PT, Joffe P, Martinsen I, Thomsen HS. Identification and quantification of gadodiamide in serum, urine,...

Cited by (293)

European fluxes of medical gadolinium to the ocean: A model based on healthcare databases
2023, Environment International
Marine ecosystems are exposed to a multitude of stresses, including emerging metals as Rare Earth Elements. The management of these emerging contaminants represents a significant environmental issue. For the past three decades, the increasing medical use of gadolinium-based contrast agents (GBCAs) has contributed to their widespread dispersion in hydrosystems, raising concerns for ocean conservation. In order to control GBCA contamination pathways, a better understanding of the cycle of these elements is needed, based on the reliable characterization of fluxes from watersheds.
Our study proposes an unprecedented annual flux model for anthropogenic gadolinium (Gd_anth) based on GBCA consumption, demographics and medical uses. This model enabled the mapping of Gd_anth fluxes for 48 European countries. The results show that 43 % of Gd_anth is exported to the Atlantic Ocean, 24 % to the Black Sea, 23 % to the Mediterranean Sea and 9 % to the Baltic Sea. Together, Germany, France and Italy contribute 40 % of Europe’s annual flux. Our study was therefore able to identify the current and future major contributors to Gd_anth flux in Europe and identify abrupt changes related to the COVID-19 pandemic.
One-step Method to Fabricate Poly(ethylene terephthalate)/Gd(OH)<inf>3</inf> Magnetic Nanofibers tTowards MRI-active Materials with High T<inf>1</inf> Relaxivity and Long-term Visibility
2022, Giant
Citation Excerpt :
However, due to their high water-solubility, CAs were rapidly dissolved in the environment. The in vivo half-lives of Gd-DTPA (13.1 minutes [48]) and gadodiamide (1.3 hours [49]) were too short for them to provide long-term MRI visibility. Thus, a water-insoluble CA with high T1 relaxation acceleration efficiency (i.e., T1 relaxivity) is needed to endow electrospun fibers with long-term positive contrast.
Magnetic resonance imaging (MRI)-active polymers exhibit unique advantages for in vivo diagnosis. Here, in order to endow electrospun fibers with long-term T₁ positive MRI visibility, MRI contrast agent (CA), Gd(OH)₃, is introduced in a new, extremely convenient method. Crucially, GdCl₃ is reacted with NaOH in situ during electrospinning, with flexibility to deliver both well-dispersed and aggregated Gd(OH)₃ clusters within a poly(ethylene terephthalate) (PET) matrix. T₁ and T₂ relaxivities of Gd(OH)₃ in PET nanofibers are studied. Well-dispersed Gd(OH)₃ (sub-nanometer in size) exhibits 34 times higher T₁ relaxivity than aggregated nanoparticles when embedded within the fibers. The morphology, structure, magnetic properties, tensile properties, imaging performance and biosafety of the PET/Gd(OH)₃ composite fibers are evaluated to identify the optimum conditions to produce new materials with balanced properties, excellent in vivo positive contrast and approximately 139 days imaging lifetime. Comparing this sample with a commercial CA, only 0.32 wt.% Gd loading is needed to attain similar MRI signal intensity. In summary, PET/Gd(OH)₃ long-term MRI-active fibers show great potential for future biomedical applications and the study also provides a promising new general strategy to enhance the MRI T₁ positive contrast of electrospun fibers of a whole host of other systems.
Stability of MRI contrast agents in high-energy radiation of a 1.5T MR-Linac
2021, Radiotherapy and Oncology
Gadolinium-based contrast is often used when acquiring MR images for radiation therapy planning for better target delineation. In some situations, patients may still have residual MRI contrast agents in their tissue while being treated with high-energy radiation. This is especially true when MRI contrast agents are administered during adaptive treatment replanning for patients treated on MR-Linac systems.
The purpose of this study was to analyze the molecular stability of MRI contrast agents when exposed to high energy photons and the associated secondary electrons in a 1.5T MR-Linac system. This was the first step in assessing the safety of administering MRI contrast agents throughout the course of treatment.
Two common MRI contrast agents were irradiated with 7 MV photons to clinical dose levels. The irradiated samples were analyzed using liquid chromatography-high resolution mass spectrometry to detect degradation products or conformational alterations created by irradiation with high energy photons and associated secondary electrons.
No significant change in chemical composition or displacement of gadolinium ions from their chelates was discovered in samples irradiated with 7 MV photons at relevant clinical doses in a 1.5T MR-Linac. Additionally, no significant correlation between concentrations of irradiated MRI contrast agents and radiation dose was observed.
The chemical composition stability of the irradiated contrast agents is promising for future use throughout the course of patient treatment. However, in vivo studies are needed to confirm that unexpected metabolites are not created in biological milieus.
Speciation analysis of Gadolinium-based contrast agents using aqueous eluent-hydrophilic interaction liquid chromatography hyphenated with inductively coupled plasma-mass spectrometry
2021, Talanta
Citation Excerpt :
These agents can be divided into macrocyclic compounds (Gd-HP-DO3A, Gd-DOTA, and Gd-BT-DO3A) and linear compounds (Gd-DTPA, Gd-DTPA-BMA, and Gd-EOB-DO3A) (Fig. S1). Because of their high complex stability, they are considered to be safe for the human body [6]. However, administration of Gd-based contrast agents for patients with renal failure involves a risk for nephrogenic systemic fibrosis (NSF) [7–9].
Gadolinium chelates are widely used as contrast agents for magnetic resonance imaging (MRI). In recent decades, the amount of Gd in river water has been increasing owing to the input of Gd-based contrast agents. To identify and quantify the Gd-based contrast agents in river water, the novel technique of hydrophilic interaction liquid chromatography (HILIC) hyphenated with inductively coupled plasma-mass spectrometry (ICP-MS) was developed. To avoid deposition of carbon on the ICP-MS interface, a mobile phase consisting of an ammonium acetate buffer diluted with pure water was applied to separate Gd-based contrast agents. Despite the absence of an organic solvent in the mobile phase, six Gd-based contrast agents, Gd-DTPA, Gd-EOB-DTPA, Gd-DOTA, Gd-DTPA-BMA, Gd-BT-DO3A, and Gd-HP-DO3A, were successfully separated. This technique was applied for river water samples. As a result, Gd-DOTA, Gd-BT-DO3A, and Gd-HP-DO3A were observed from the sample near the outfall of a wastewater treatment plant (WWTP), indicating that at least some of the Gd-based contrast agents are passed through treatment in a WWTP. In addition to Gd-based contrast agents, unidentified Gd compounds were found to be present in river water. These results infer that transformation and/or dissociation of Gd chelates may be caused during the treatment procedure in a WWTP.
Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
2021, Kidney Medicine
Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m²; upper bounds of the 95% confidence intervals: 0.07% overall, 0.2% for stage 5D chronic kidney disease [CKD], 0.5% for stage 5 CKD and no dialysis). No unconfounded cases of NSF have been reported for the only available group III GBCM (gadoxetate disodium). Depending on the clinical indication, the potential harms of delaying or withholding group II or group III GBCM for an MRI in a patient with acute kidney injury or eGFR less than 30 mL/min per 1.73 m² should be balanced against and may outweigh the risk of NSF. Dialysis initiation or alteration is likely unnecessary based on group II or group III GBCM administration.
Anthropogenic gadolinium in freshwater and drinking water systems
2020, Water Research
The increasing use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging is leading to widespread contamination of freshwater and drinking water systems. Contrary to previous assumptions that GBCAs are stable throughout the water cycle, they can degrade. The stability of GBCAs depends largely on their organic ligands, but also on the physicochemical conditions. There is specific concern regarding UV end-of-pipe water treatments, which may degrade GBCAs. Degradation products in drinking water supplies can increase the risk of adverse health effects. This is of particular relevance where the raw water for drinking water production has a higher proportion of recycled wastewater. GBCAs concentrations in aquatic systems, often referred to as anthropogenic gadolinium, are determined using a variety of calculation methods. Where anthropogenic gadolinium concentrations are low, the inconsistent use of these methods results in high discrepancies and high levels of uncertainty. The current COVID-19 crisis will, in the short-term, drastically decrease the input of GBCAs to freshwater systems. Temporal variations in anthropogenic gadolinium concentrations in river water can be used to better understand river-aquifer interactions and groundwater flow velocities. Collecting urine from all patients following MRI examinations could be a way forward to halt the generally increasing concentrations of Gd in drinking water systems and recover this technologically critical element.

View all citing articles on Scopus

View full text

Original investigationPharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis

Rationale and Objectives.

Materials and Methods.

Results.

Conclusion.

J Pharmaceut Biomed Analg

Magn Reson Imaging

Eur J Radiol

A phase I clinical trial with gadodiamide, a nonionic magnetic resonance imaging enhancement agent

Invest Radiol

Pharmacokinetics of gadodiamide in patients with moderately impaired renal function

Acad Radiol

Pharmacokinetics of Gd-DTPA in patients with chronicrenal failure

Invest Radiol

Pharmacokinetics and tolerance of Gd-DOTA (DOTAREM) in healthy volunteers and in patients with chronic renal failure

Eur Radiol

Hemodialysis for elimination of nonionic contrast medium iohexol after angiography in patients with impaired renal function

Nephron

Pharmakokinetik von gadolinium-DTPA bei dialysepflichtiger chronischer niereninsuffizienz

Roe Foe

The dialysability of Gd-DTPA

A simple method for the determination of glomerular filtration rate

Scand J Clin Lab Invest

Original investigation
Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis